Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1361 - Cell-free circulating tumor DNA (CFTDNA) – in Cervical Carcinoma-a Diagnostic and screening marker (31P)


18 Nov 2017


Poster lunch


Translational Research;  Cervical Cancer


H B Govardhan


Annals of Oncology (2017) 28 (suppl_10): x7-x15. 10.1093/annonc/mdx653


H.B. Govardhan1, I. Khaleel1, N. Sarkar1, S. Supriya1, M.N. Suma2

Author affiliations

  • 1 Radiation Oncology, Kidwai Memorial Institute of Oncology, 560029 - Bangalore/IN
  • 2 Pathology, Kidwai Memorial Institute of Oncology, 560029 - Bangalore/IN


Abstract 1361


There are many diagnostic modalities are developed or under development to improve the diagnostic ability and to prognosticate in patients with cervical carcinoma. Cell-free circulating tumor DNA (CFTDNA) is one among them. In this study we are aiming to know the diagnostic ability at diagnosis of CFTDNA and to create genetic screening tool to detect cervical carcioma.


A total of 25 patients with locally advanced squamous cell carcinoma of cervical cancer (stage IIA-IIIB) were tested prospectively with a 50-gene tumor panel in a NABL accredited laboratory. 4 ml serum was collected, CfTDNA was isolated and they were checked for single nucleotide variants (SNVs) genes/copy number variants (CNVs) by using NGS and tumor FFPE blocks were again rechecked by NGS or PCR for the same genetic alterations.


Average patient age was 50.5 (range 35-83). In 23/25 (88.8%) patients, CfTDNA was detected and sufficient to carry under NGS. Out of 50 genes, around 31 genetic alterations were detected. Mean genetic alteration was 4.7 (2-15). In 4/23 (17%) patients are more than 8 genomic alteration detected, 4/23 (17%) patients had 5-8 genetic alteration, remaining 15/23 (67%) patients had less than 4 genetic alteration. Most common SNVs detected included were, CDKN2A- 12/23 patients, PIK3CA-11/23 patients, TP53 -11/23 (87.5%) patients, PTEN -7/23 patients, BRAF-7/23 patients, STK11- 7/23 patients, VHL- 6/23 patients, EGFR, CTNNB1, GNAS, KIT, SMAD3 were 5/23 patients, SMARCB1, SMO, RET, FBXW7, ERBB2, CSF1R, CDH1, APC- 3/23 each, AKT1, EBB4, FGFR3, FGFR3. FLT3, HRAS, JAK3, MET, NOTCH1, NPM1, KRAS, PTPN11- 1 or 2/23 patients. On combination of these genetic alterations - EGFR, KIT, PTEN, PIK3CA, TP 53, VHL are the main alterations and combination of these gene (Govardhan Diagnostic and Screening Genetic Module for Cervix Cancer), at least one genetic alteration among combination was found in 100% patients at any point of time.


CfTDNA can be easily demonstrable and can be used as a noninvasive diagnostic tool in cervical carcinoma. The proposed genetic screening module needs to be further investigated at large scale with different races, ethnicities and countries.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.